Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | ACHE | P22303 | 3/20 | 0.56 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 7/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL345517 | 1.00 | CA1 (0.56) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL8603749 | 1.00 | CA1 (0.56) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL345882 | 0.94 | MTNR1A (0.60) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL345881 | 0.94 | MTNR1A (0.60) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL8603880 | 0.94 | MTNR1A (0.60) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL970670 | 0.88 | CA1 (0.56) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL10225789 | 0.87 | MTNR1A (0.51) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL8066286 | 0.87 | CA1 (0.59) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL9361562 | 0.87 | CA1 (0.55) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL8076235 | 0.87 | CA1 (0.55) | CA1CA2ACHEMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0683236-B1 | Enzymatic process for the preparation of optical active tetralin-derivatives | SANOFI SYNTHELABO (FR) | 2000-08-09 | — | — | EP | claimed |
| EP-0683236-A1 | Enzymatic process for the preparation of optical active tetralin-derivatives | SANOFI (FR) | 1995-11-22 | — | — | EP | claimed |
| EP-0678579-A1 | Enzymatic process for the preparation of optical active tetralin-derivatives | MIDY S.p.A. (IT) | 1995-10-25 | — | — | EP | claimed |
| US-20120178781-A1 | KAPPA OPIOID RECEPTOR LIGANDS | RESEARCH TRIANGLE INSTITUTE (US) | 2012-07-12 | — | — | US | disclosed |
| US-8173678-B2 | Kappa opioid receptor ligands | RESEARCH TRIANGLE INSTITUTE (US) | 2012-05-08 | — | — | US | disclosed |
| EP-1848275-B1 | KAPPA OPIOID RECEPTOR LIGANDS | RES TRIANGLE INST (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20110065743-A1 | KAPPA OPIOID RECEPTOR LIGANDS | RESEARCH TRIANGLE INSTITUTE (US) | 2011-03-17 | — | — | US | disclosed |
| US-7872023-B2 | administering 6-Hydroxy-1,2,3,4-tetrahydro-naphthalene-2(-)-carboxylic acid{1-[4-(3-hydroxyphenyl)-(3R)-(4R)-trans-dimethyl-piperidinylmethyl]-(2S)-methylpropyl}-amide, for the treatment of drug abuse and dependence | RESEARCH TRIANGLE INSTITUTE (US) | 2011-01-18 | — | — | US | disclosed |
| US-5719308-A | Enzymatic process for the preparation of optically active tetralin derivatives | SANOFI (FR) | 1998-02-17 | — | — | US | disclosed |
| US-5573949-A | Enzymatic process for the preparation of optically active Tetrahydro-2-naphthoic acids | SANOFI (FR) | 1996-11-12 | — | — | US | disclosed |
| US-5130339-A | Intestine and uterine motility modulators for reduction of intraocular pressure for glaucoma treatment | SANOFI (FR) | 1992-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065743-A1 | KAPPA OPIOID RECEPTOR LIGANDS | OPRK1, OPRD1, OPRM1 | CA1 3185/4885CA2 4530/4885ACHE 929/4885 |
| US-20120178781-A1 | KAPPA OPIOID RECEPTOR LIGANDS | OPRK1, OPRD1, OPRM1 | CA1 3185/4885CA2 4530/4885ACHE 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.